On April 2, 2015, FDA conducted a public meeting on Breast Cancer Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of breast cancer on daily life and patients’ views on currently available therapies to treat the condition.
This website will be updated as meeting materials are developed.
April 2, 2015
1:00 pm to 5:00 pm
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
Enter at Building 1 to clear security
(Information about arrival to FDA’s White Oak campus)
To register for this meeting, visit: online registration
Registration is closed.
Submitting comments to the public docket:
In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on June 2, 2015.
Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED] Flyer for Breast Cancer Meeting(PDF - 111KB)
- Agenda for Breast Cancer Meeting (PDF - 132KB)
Breast Cancer Meeting Slides(PDF - 771KB) Breast Cancer Meeting Transcript(PDF - 7.5MB) The Voice of the Patient Report: Breast Cancer(PDF - 375KB)